Annual CFF
$271.38 M
+$267.21 M+6418.76%
31 December 2023
Summary:
Viking Therapeutics annual cash flow from financing activities is currently $271.38 million, with the most recent change of +$267.21 million (+6418.76%) on 31 December 2023. During the last 3 years, it has risen by +$270.43 million (+28465.89%). VKTX annual CFF is now -9.62% below its all-time high of $300.27 million, reached on 31 December 2018.VKTX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$2.52 M
-$383.00 K-13.18%
30 September 2024
Summary:
Viking Therapeutics quarterly cash flow from financing activities is currently $2.52 million, with the most recent change of -$383.00 thousand (-13.18%) on 30 September 2024. Over the past year, it has increased by +$2.60 million (+3508.11%). VKTX quarterly CFF is now -99.58% below its all-time high of $606.04 million, reached on 31 March 2024.VKTX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$611.65 M
+$2.60 M+0.43%
30 September 2024
Summary:
Viking Therapeutics TTM cash flow from financing activities is currently $611.65 million, with the most recent change of +$2.60 million (+0.43%) on 30 September 2024. Over the past year, it has increased by +$329.71 million (+116.95%). VKTX TTM CFF is now -29.96% below its all-time high of $873.23 million, reached on 31 March 2024.VKTX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
VKTX Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +6418.8% | +3508.1% | +117.0% |
| 3 y3 years | +10000.0% | +1085.2% | +8282.2% |
| 5 y5 years | -9.6% | +3354.8% | +10000.0% |
VKTX Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | >+9999.0% | -99.6% | +150.4% | -30.0% | +9088.3% |
| 5 y | 5 years | -9.6% | >+9999.0% | -99.6% | +150.4% | -30.0% | +9088.3% |
| alltime | all time | -9.6% | >+9999.0% | -99.6% | +150.4% | -30.0% | +9088.3% |
Viking Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $2.52 M(-13.2%) | $611.65 M(+0.4%) |
| June 2024 | - | $2.90 M(-99.5%) | $609.06 M(-30.3%) |
| Mar 2024 | - | $606.04 M(>+9900.0%) | $873.23 M(+221.8%) |
| Dec 2023 | $271.38 M(+6418.8%) | $188.00 K(-354.1%) | $271.38 M(-3.7%) |
| Sept 2023 | - | -$74.00 K(-100.0%) | $281.94 M(-0.0%) |
| June 2023 | - | $267.08 M(+6283.3%) | $282.02 M(+2012.0%) |
| Mar 2023 | - | $4.18 M(-61.1%) | $13.35 M(+220.8%) |
| Dec 2022 | $4.16 M(-39.5%) | $10.75 M(>+9900.0%) | $4.16 M(-163.7%) |
| Sept 2022 | - | $10.00 K(-100.6%) | -$6.54 M(-3.9%) |
| June 2022 | - | -$1.59 M(-68.2%) | -$6.80 M(+105.2%) |
| Mar 2022 | - | -$5.01 M(<-9900.0%) | -$3.32 M(-148.2%) |
| Dec 2021 | $6.88 M(+624.2%) | $47.00 K(-118.4%) | $6.88 M(-5.7%) |
| Sept 2021 | - | -$256.00 K(-113.5%) | $7.30 M(-3.9%) |
| June 2021 | - | $1.90 M(-63.4%) | $7.59 M(+24.3%) |
| Mar 2021 | - | $5.19 M(+1018.8%) | $6.11 M(+542.9%) |
| Dec 2020 | $950.00 K(+7.1%) | $464.00 K(+1154.1%) | $950.00 K(+32.9%) |
| Sept 2020 | - | $37.00 K(-91.1%) | $715.00 K(-4.8%) |
| June 2020 | - | $416.00 K(+1160.6%) | $751.00 K(+26.2%) |
| Mar 2020 | - | $33.00 K(-85.6%) | $595.00 K(-32.9%) |
| Dec 2019 | $887.00 K(-99.7%) | $229.00 K(+213.7%) | $887.00 K(-11.4%) |
| Sept 2019 | - | $73.00 K(-71.9%) | $1.00 M(-99.4%) |
| June 2019 | - | $260.00 K(-20.0%) | $168.41 M(-29.3%) |
| Mar 2019 | - | $325.00 K(-5.2%) | $238.30 M(-20.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2018 | $300.27 M(+1240.5%) | $343.00 K(-99.8%) | $300.27 M(-4.6%) |
| Sept 2018 | - | $167.49 M(+138.8%) | $314.69 M(+112.2%) |
| June 2018 | - | $70.15 M(+12.6%) | $148.32 M(+80.5%) |
| Mar 2018 | - | $62.30 M(+322.0%) | $82.17 M(+266.8%) |
| Dec 2017 | $22.40 M(+116.5%) | $14.76 M(+1228.8%) | $22.40 M(+158.2%) |
| Sept 2017 | - | $1.11 M(-72.2%) | $8.68 M(+13.1%) |
| June 2017 | - | $4.00 M(+58.6%) | $7.67 M(-40.7%) |
| Mar 2017 | - | $2.52 M(+143.1%) | $12.93 M(+24.9%) |
| Dec 2016 | $10.35 M(-53.4%) | $1.04 M(+858.7%) | $10.35 M(+11.5%) |
| Sept 2016 | - | $108.30 K(-98.8%) | $9.28 M(+9.6%) |
| June 2016 | - | $9.26 M(<-9900.0%) | $8.47 M(-61.8%) |
| Mar 2016 | - | -$57.30 K(+103.2%) | $22.17 M(-0.2%) |
| Dec 2015 | $22.21 M(+924.8%) | -$28.20 K(-96.0%) | $22.21 M(-1.9%) |
| Sept 2015 | - | -$704.70 K(-103.1%) | $22.64 M(-5.1%) |
| June 2015 | - | $22.96 M(<-9900.0%) | $23.86 M(+1010.0%) |
| Mar 2015 | - | -$17.90 K(-104.4%) | $2.15 M(-0.8%) |
| Dec 2014 | $2.17 M(+740.5%) | $402.40 K(-21.5%) | $2.17 M(+22.8%) |
| Sept 2014 | - | $512.80 K(-59.1%) | $1.77 M(+40.9%) |
| June 2014 | - | $1.25 M(>+9900.0%) | $1.25 M(+481.5%) |
| Mar 2014 | - | $0.00(-100.0%) | $215.40 K(0.0%) |
| Dec 2013 | $257.90 K | - | - |
| June 2013 | - | $215.40 K(>+9900.0%) | $215.40 K(>+9900.0%) |
| Mar 2013 | - | $0.00 | $0.00 |
FAQ
- What is Viking Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Viking Therapeutics?
- What is Viking Therapeutics annual CFF year-on-year change?
- What is Viking Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Viking Therapeutics?
- What is Viking Therapeutics quarterly CFF year-on-year change?
- What is Viking Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Viking Therapeutics?
- What is Viking Therapeutics TTM CFF year-on-year change?
What is Viking Therapeutics annual cash flow from financing activities?
The current annual CFF of VKTX is $271.38 M
What is the all time high annual CFF for Viking Therapeutics?
Viking Therapeutics all-time high annual cash flow from financing activities is $300.27 M
What is Viking Therapeutics annual CFF year-on-year change?
Over the past year, VKTX annual cash flow from financing activities has changed by +$267.21 M (+6418.76%)
What is Viking Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of VKTX is $2.52 M
What is the all time high quarterly CFF for Viking Therapeutics?
Viking Therapeutics all-time high quarterly cash flow from financing activities is $606.04 M
What is Viking Therapeutics quarterly CFF year-on-year change?
Over the past year, VKTX quarterly cash flow from financing activities has changed by +$2.60 M (+3508.11%)
What is Viking Therapeutics TTM cash flow from financing activities?
The current TTM CFF of VKTX is $611.65 M
What is the all time high TTM CFF for Viking Therapeutics?
Viking Therapeutics all-time high TTM cash flow from financing activities is $873.23 M
What is Viking Therapeutics TTM CFF year-on-year change?
Over the past year, VKTX TTM cash flow from financing activities has changed by +$329.71 M (+116.95%)